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Background
Nucleoside reverse transcriptase inhibitors (NRTIs) were
the first drugs introduced for treatment of human
immunodeficiency virus-1 (HIV-1) infection. These
NRTIs may be cyclic or acyclic analogs of natural
nucleosides. Both these analogs interact at active site on
HIV-RT and compete with indigenous nucleosides/
nucleotides, and thus, divert enzyme activity in man-
made direction. All NRTIs follow three phosphorylation
steps that convert the parent compound successively to
5’-triphosphate. These 5’-triphosphates act as alternate
substrate for HIV-RT, and lead to chain termination
when incorporated into the DNA chain as they don’t
provide the 3’-OH function.
Method
Development of acyclic allylic nucleoside analogs, which
act as NRTIs against HIV, involves both the computa-
tional and synthetic methods. Designing is done keeping
the Lipinski’s Rule of Five in focus and SAR studies
were performed using DS 3.0 software. The ADMET
descriptor and TOPKAT protocol available in DS 3.0
were used to predict these properties. The Lipinski’s
Rule of Five was also used to determine the biological
activity or druglikeness of the designed inhibitors.
Result
All acyclouracil analogues formed 3-10 bonds with
amino acids constituting the dNTP site on HIV-RT.
The amino acids that interact with these molecules are
Gln44, Lys46, Lys65, Arg72, Asp110, Asp113, Gln151,
Asp185, Pro217, His221, Lys223 through H-bonding
and π-π interaction.
Conclusion
On the basis of SAR studies, acyclic allylic analogs of
uracil bearing carbonyl and sulphonyl groups at N-3
position are expected to be probable lead molecules
against HIV-RT. Biological screening is under process.
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